The guy who started up this company is an ex-hedge fund operator. He has to get his hands on a lot of money to pay back furious investors from the hedge fund losses. The distribution of the drug in question is tightly controlled buy the maker. It is not available through pharmacies but directly to hospitals. Supposedly, this type of distribution makes is almost impossible to get enough of the drug to reverse engineer it and make a generic version.
It shouldn’t be necessary to “reverse engineer” it.
If it was patented, the patent disclosure should explain to a “skilled practitioner of the art” how to do it.